

### Pharmaceutical **POOL**

### Dr. Roger **POMERANTZ**

Merck Appoints Head of Infectious Diseases



Merck has named Roger Pomerantz, M.D., senior VP of Merck Research Laboratories (MRL) and infectious diseases franchise head. Dr. Pomerantz spent the last five years at

Johnson & Johnson, where he most recently served as global head of infectious diseases and president of Peninsula Pharmaceuticals. He received an M.D. from The Johns Hopkins University School of Medicine.

### Biotechnology POOL

### Stephen **DAVIS**

Ardea Biosciences Names Operating Chief



Ardea Biosciences, which is focused on developing therapeutics for the treatment of gout, cancer, and HIV, has named Stephen Davis as executive VP and chief operating officer. Mr. Davis was

previously president and CEO of Neurogen. He received a J.D. from Vanderbilt University.


### Dr. Thomas **HOFSTAETTER**Dr. Alan **SHAW**

VaxInnate Announces CEO Change

VaxInnate, a biotechnology firm pioneer-



ing breakthrough technology for developing novel vaccines, has named Thomas Hofstaetter, Ph.D., president and CEO.



University of Tuebingen in Germany.

As CEO, Dr. Hofstaetter succeeds Alan Shaw, Ph.D., who has become chairman of VaxInnate's board and assumed the newly created role of chief scientific officer for the company. Dr. Shaw received a Ph.D. in molecular biology and biochemistry from the Medical College of Ohio.

### Dr. Sven Ante (Bill)

### **LUNDBERG**

### Dr. Karen **TUBRIDY**

Taligen Expands Development Expertise

Taligen Therapeutics, a company developing therapies that regulate the complement system to treat inflammatory and immune diseases, has named Sven Ante (Bill) Lundberg,



M.D., chief medical officer. Dr. Lundberg has held senior clinical and medical affairs roles in both large pharmaceutical and emerging biopharmaceutical companies. He holds an M.D. from Stanford Medical School.

Karen Tubridy, Pharm.D., has joined Taligen as VP, clinical operations and regulatory affairs. Dr. Tubridy was most recently senior director of clinical opera-



tions for Biogen Idec's hemophilia franchise and VP of clinical operations at Syntonix Pharmaceuticals. She received a Pharm.D. from the Massachusetts College of Pharmacy and Allied Health Sciences.

### Varun **NANDA**

Former Genentech Executive Joins Dendreon

Dendreon, a company targeting cancer through the discovery, development, and commercialization of novel therapeutics, has appointed Varun Nanda senior VP of global commercial opera-



tions. Mr. Nanda most recently served as senior VP and global head of oncology at Genentech. He received an MBA from Eastern Illinois University.

### Biopharmaceutical **POOL**

## Dr. Robert **ARBEIT**Dr. Nicola **LA MONICA**Dr. Timothy **SULLIVAN**

Idera Pharmaceuticals Adds VPs to Development Group

Idera Pharmaceuticals has bolstered its development leadership team with the appointment of three VPs. Idera develops drug candidates to treat infectious diseases, autoimmune and inflammatory diseases, cancer, and respiratory diseases.



Robert Arbeit, M.D., has joined Idera as VP of clinical development. Dr. Arbeit was most recently VP of clinical development at Paratek Pharmaceuticals. He received an M.D. from Yale University School of Medicine.

Idera has named Nicola La Monica, Ph.D., VP of biology.

Dr. La Monica was previously director of antiviral research at IRBM, a division of Merck Research Laboratories. He earned a Ph.D. in microbiology from Columbia University.

Timothy Sullivan, Ph.D., has been promoted to VP of development programs and alliance management, from VP of development programs.

### Dr. Robert **GOULD** Jason **RHODES**

**Epizyme Announces Leadership Shifts** 



Epizyme, a company translating key discoveries in the field of epigenetics into novel pharmaceuticals, has appointed Robert Gould, Ph.D., CEO, succeeding Kazumi Shiosaki, Ph.D., who remains a member of the board.



Dr. Gould has been a board member for two years and joins the company from the Broad Institute, where he was director of novel therapeutics. He obtained

degrees from Spring Arbor College and The University of Iowa.

Epizyme also has named Jason Rhodes executive VP and chief business officer. Mr. Rhodes was previously VP, business development at Alnylam Pharmaceuticals. He received an MBA from the Wharton School of the University of Pennsylvania.

### John **ORWIN** Sylvia WHEELER

Affymax Selects President



John Orwin has joined Affymax as president and chief operating officer. Affymax is a developer of novel drugs to improve the treatment of serious and often lifethreatening conditions. Mr.

Orwin was most recently senior VP, BioOncology business unit, for Genentech. He received an MBA from New York University.

In other moves, Affymax has promoted Sylvia Wheeler to VP, corporate communications. Ms. Wheeler received an MBA from the University of San Francisco.

### Drug-Delivery **POOL**

### Peter CIANO

Tris Pharma Hires Key Executive

Tris Pharma, a specialty pharmaceutical company that develops innovative drug delivery technologies, has appointed Peter Ciano VP of corporate development. Mr. Ciano previously worked as a business development consultant for Tris. He is a pharmacist by training and holds an MBA in finance.

### Device/Diagnostic POOL

### John **BUHLER**

SenoRx Announces CEO Succession



SenoRx has appointed John Buhler CEO following the March 2010 death of Chairman and CEO Lloyd Malchow. Mr. Buhler has served as acting CEO of SenoRx since Mr. Malchow went

on medical leave. SenoRx develops, manufactures, and sells minimally invasive medical devices used for the diagnosis and treatment of breast cancer.

### Dr. Frank PITZER

Roche NimbleGen Appoints CEO

Roche NimbleGen, a division of Roche and global provider of microarray tools for genetic discovery and analysis, has appointed Frank Pitzer, Ph.D., CEO. Dr. Pitzer most recently served as



head of divisional quality and regulatory affairs for Roche Diagnostics. He earned a Ph.D. in biology from Max Planck Institute for Biochemistry in Martinsried, Germany.

### Emerging **POOL**

### Dr. Susan **FROSHAUER** Mark **LEUCHTENBERGER**

Rib-X Makes Leadership Changes

Rib-X Pharmaceuticals has named Susan Froshauer, Ph.D., to the newly created role of chief scientific officer. Dr. Froshauer was previously CEO of Rib-X, a development-stage antibiotics company.

Mark Leuchtenberger has been appointed president and CEO of Rib-X. Mr. Leuchtenberger joins the company from Targanta Therapeutics, where he served as president and CEO. He received an MBA from Yale School of Management.



### Association **POOL**

### Dr. Flizabeth **BLACKBURN** Dr. Judy **GARBER**

**AACR Swears In New President** 



Elizabeth Blackburn, Ph.D., has been named president of American Association for Cancer Research (AACR) for the 2010-2011 term. Dr. Blackburn is a professor of biology and physiology in the Department of Biochemistry and Biophysics at the University of California, San Francisco.



AACR has elected Judy Garber, M.D., MPH, as presidentelect. Dr. Garber is the director

of the Cancer Risk and Prevention Program at the Dana-Farber Cancer Institute, associate professor of medicine at Harvard Medical School, and associate physician of medicine and attending physician of medical service at Brigham and Women's Hospital.

Founded in 1907, the AACR is the world's oldest and largest professional organization dedicated to advancing cancer research.

### Agency **POOL**

Ben **BLOUNT** Sara **CABIN** 

Bob **DEBARTOLO** 

Pete **DENSMORE** 

Cori **DILLER-DANTE** 

Steve **DUMAS** 

Sharlene **KING** 

Emily RAY

Chad **SMITH** 

**Brook STENSGAARD** 

Ryan VAN PELT

Goble & Associates Makes Staff Changes

Healthcare communication agency Goble & Associates (GA) has announced a number of




promotions and new hires in response to growing client demand.

Ben Blount has joined GA as a senior art director. Mr. Blount has previously worked at Williams-Labadie and Abelson-Taylor. He received an MFA in book and paper arts from Columbia College Chicago.




Sara Cabin has been named art director. Ms. Cabin was most recently with Proof, an internal agency at Beam Global Spirits & Wine.





Pete Densmore has joined GA as an

account supervisor. Mr. Densmore has several years of healthcare marketing experience, most recently with Purohit Navigation.




Steve Dumas has been promoted to account executive. Mr. Dumas joined GA in 2007 as an

account manager.




Sharlene King has joined GA as a digital designer. Ms.


King was previously a graphic designer at Kaplan Financial.






Chad Smith has been promoted to account director. Mr. Smith first joined GA in 2006 as an account supervisor.









MedThink Adds to Digital, Account Groups

Full-service healthcare communications company Med-Think Communications has announced new hires in its digital practice and promotional account services group. Med-Think has hired Bridget Dean and Laura Dutterer as account executives. Ms. Dean was most recently an account manager at VML, and Ms. Dutterer joins MedThink from Ulanguzi Creative Strategies, where she was an account executive.



Other additions to the digital practice include Robert Harrison

as Web developer and Glenn Knapp as Web designer. Mr. Knapp was previ-



Diego Union-Tribune. Edward Leon has joined Med-Think as account director, medical communications. Mr. Leon most recently worked as senior program director and VP, client services for S+R Medical Communications. He holds an MBA from the University of Michigan and is a licensed pharmacist in North Carolina and Michigan.

ously Web designer with The San



MedThink has appointed Michael Szumera VP, public relations practice lead. Most recently, Mr. Szumera was director, public relations and marketing communications, at Lazar Partners.



**Conectics Appoints President** 



Conectics, a CommonHealth professional media planning and buying unit, has promoted Rebecca Frederick to president from general manager. Ms. Frederick maintains primary responsi-

bility for Conectics and continues to maintain and evolve all of the company's media planning, buying, and placement and to oversee all client management, new-business initiatives, research, and analytics.



Former Campbell Alliance Advisor Joins Maxcess



James Harmon has been named executive VP, managing director, of Maxcess Managed Markets, a specialty provider of strategic market insight, planning, research, and communica-

tions services to the pharmaceutical industry. Maxcess is a Publicis Health Care Communications Group (PHCG) company.

Mr. Harmon was most recently an executive advisor with the managed markets practice and the Pharmaceutical Institute of Campbell Alliance.



Steven **HÉBERT** 

LyonHeart Names Creative Director



Healthcare communications company LyonHeart has hired Steven Hébert as executive VP, executive creative director. Mr. Hébert joins LyonHeart from The CementBloc. LyonHeart is

part of Diversified Agency Services, the marketing services network of Omnicom Group.



**HC&B** Adds to Account Team



Independent agency HC&B Healthcare Communications has hired Kerry Kessler as account supervisor. Ms. Kessler is working on three accounts: Texas Oncology Menninger Clinic, and

GeoDigm. She joins HC&B from JWT Advertising, where she was an account supervisor.



### Amy **KLUG**Chris **STEELE**

AbelsonTaylor Promotes Senior Executives



Independent healthcare advertising agency AbelsonTaylor has promoted Amy Klug and Chris Steele to the role of senior account executive, from account executive.



Ms. Klug joined AbelsonTaylor in 2006 and has been responsible for two new product launches in the areas of hypertension and hematology. Mr. Steele is responsible for products in the pain

management area. He joined AbelsonTaylor in 2006.

### Dr. Boris **KUSHKULEY**

CommonHealth Promotes President of Qi



Healthcare communications network CommonHealth, a WPP company, has promoted Boris Kushkuley, Ph.D., to president of Qi, its full-service digital group. Dr. Kushkuley was previously

Qi's general manager.

### Pete **PARADOSSI**

Fleishman-Hillard Selects Healthcare Practice Leader



Pete Paradossi has joined public relations firm Fleishman-Hillard, part of Omnicom Group, as a senior VP and healthcare practice leader. Mr. Paradossi most recently was an executive leading

corporate and business communications for Bristol-Myers Squibb's healthcare group.

### Erinn WHITE

HealthSTAR Public Relations Appoints CEO



Erinn White has been promoted to president and CEO of HealthSTAR Public Relations (HSPR). HSPR, part of the HealthSTAR Communications network, is a full-service agency.

Ms. White joined HSPR in 2003 and most recently served as executive VP and general manager.

#### CRO POOL

### Terry **LADD**Dr. Richard **MARTIN**

NexMed Taps VPs for Operating Subsidiaries

NexMed, a specialty CRO with a pipeline of products based on the NexACT drug-delivery technology, has expanded the senior management team. Terry Ladd has been named VP of business development for Bio-Quant, NexMed's discovery preclinical service subsidiary. He received an M.A. from the University of Sherbrooke in Quebec, Canada, and an MBA in marketing and finance from McGill University.

Richard Martin, Ph.D., has been appointed VP of chemistry for NexMed (U.S.A.), with responsibility for leading the development work for the next generation of NexACT technology and NexACT-based products. He received a Ph.D. in organic chemistry from the University of Toronto and completed his post-doctoral research at The Scripps Research Institute.

### Service **POOL**

# Carl **KUNZ**Keith **MANGAS**Chris **ROFIDAL**Judy **STEIN**

**Qforma Adds Executives** 

Qforma, a healthcare data analytics and predictive modeling company, has appointed Carl Kunz, Keith Mangas, and Chris Rofidal as business development executives. Mr. Kunz most recently was VP of sales operations and strategy at Baxter Healthcare.

Mr. Mangas has held multiple sales and marketing positions during his healthcare industry career.

Mr. Rofidal most recently has brought his man-

aged markets expertise to such start-up companies as Reliant Pharmaceuticals and GTx.

Qforma has appointed Judy Stein director, client services. Ms. Stein's responsibilities include developing and implementing customized project plans.

Ms. Stein most recently was senior manager at GE Healthcare Performance Solutions.





### Ken MILLER

Zitter Group Names Lead for Boston Area



The Zitter Group, a managed care consultancy and insights provider for the biopharmaceutical industry, has appointed Ken Miller VP, business development and strategic client lead for all

greater Boston area biopharmaceutical clients.

### Mary **SOBIECHOWSKI**

Kantar Health Appoints Information Chief

Kantar Health, a healthcarefocused global consultancy and marketing insights company, has appointed Mary Sobiechowski chief information officer. Ms. Sobiechowski was previously chief information officer and



worldwide director of technology for Sudler & Hennessey.

### Technology **POOL**

### Dr. Laurent **SCHOCKMEL**

Cegedim Appoints Chief Strategy Officer

Cegedim Dendrite, a provider of CRM solutions, has named Laurent Schockmel chief strategy officer. Mr. Schockmel was previously Cegedim's chief operating officer of the Americas. He is a doctor in veterinary medicine and holds an MBA from ESSEC Business School.

feedback@pharmavoice.com.



MBA from ESSEC Business School. ◆

Send your personnel announcements to

SEE DIGITAL EDITION FOR BONUS CONTENT
WWW.PHARMAVOICE.COM

### Pharmaceutical **POOL**

### Dr. Ludwig **HANTSON**

Former Novartis Executive Joins Baxter International

Baxter International has appointed Ludwig Hantson, Ph.D., corporate VP and president, international. Dr. Hantson joins Baxter from Novartis, where he served as CEO, Pharma North America. He received a Ph.D. in motor rehabilitation and physical therapy from the University of Louvain in Belgium.

### Biotechnology POOL

### Dr. David **MEEKER**

Genzyme Selects Operating Chief

Global diversified biotechnology company Genzyme has appointed Executive VP David Meeker, M.D., to the newly created role of chief operating officer. Dr. Meeker is responsible for Genzyme's commercial organization, overseeing the company's business units, country management organization, and global market access functions. He received an M.D. from the University of Vermont College of Medicine and completed the advanced management program at Harvard Business School.

### Biopharmaceutical **POOL**

### Georgina KILFOIL

Anthera Expands Development Group

Anthera Pharmaceuticals, a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, has hired Georgina Kilfoil for the newly created role of senior VP of product development and clinical operations. Ms. Kilfoil was previously a project management consultant with InClin. She received an MBA from the Australian Graduate School of Management in Sydney.

### Andrew **KOVEN**

Inspire Names Chief Legal Officer

Inspire Pharmaceuticals, a biopharmaceuti-

cal company focused on researching, developing, and commercializing prescription pharmaceutical products for ophthalmic and pulmonary diseases, has appointed Andrew Koven to the newly created position of executive VP and chief administrative and legal officer.

Mr. Koven was previously executive VP, general counsel, and corporate secretary of Sepracor. He received an LL.B. from Dalhousie University Law School in Halifax, Nova Scotia, and an LL.M. from Columbia University Law School.

### Nicholas LABELLA

Insmed Appoints Scientific Chief

Nicholas LaBella Jr. has joined Insmed in the newly created role of chief scientific officer. Mr. LaBella has 30 years of pharmaceutical industry experience in various functions and most recently served as VP of development and regulatory affairs at Cardiokine. A registered pharmacist, he received an M.S. from the Arnold & Marie Schwartz College of Pharmacy at Long Island University.

### Specialty **POOL**

### Dr. Philip **ARLEN**

Neogenix Oncology Appoints CEO

Philip Arlen, M.D., has been named CEO of Neogenix Oncology, a therapeutics and diagnostics company focused on developing new products targeting a broad range of cancers. Dr. Arlen joined Neogenix as president and chief medical officer in July 2008.

He received an M.D. from Medical College of Georgia's School of Medicine.

### Dr. Errol **DE SOUZA**Dr. Solomon **STEINER**

**Biodel Announces Leadership Changes** 

Errol De Souza, Ph.D., has joined Biodel as president and CEO as the specialty biopharmaceutical company prepares for the potential approval and commercialization of its first product, VIAject, to treat diabetes.

Before joining Biodel, he served as a pharmaceutical and biotechnology consultant. Dr. De Souza earned a Ph.D. in neuroendocrinology from the University of Toronto and

received his postdoctoral fellowship in neuroscience from The Johns Hopkins University School of Medicine.

Dr. De Souza succeeds Biodel Co-Founder Solomon Steiner, Ph.D., who has been named the company's chief scientific officer.

### Device/Diagnostic **POOL**

### Dr. Albert **LUDERER**

Integrated Diagnostics Selects CEO

Personalized diagnostics company Integrated Diagnostics has named Albert Luderer, Ph.D., CEO. Dr. Luderer was previously president and CEO of BioTrove. He received a Ph.D. from Rutgers University and performed postgraduate work in immunology at Jefferson Medical College.

### Emerging **POOL**

### Paul **WESTBERG**

Versartis Appoints VP

Versartis, an emerging biotechnology company developing novel therapeutics for patients with metabolic diseases and endocrine disorders, has named Paul Westberg senior VP, business development. Most recently, Mr. Westberg was VP, business development at Bayhill Therapeutics. He received an MBA from the Walter A. Haas School of Business at the University of California, Berkeley.

#### CRO POOL

#### J. Scott **TARRANT**

**RRD International Names Business Officer** 

RRD International, a strategy-driven biotech and pharmaceutical product development company, has hired J. Scott Tarrant as chief business officer. Mr. Tarrant was previously engaged by RRD to help chart the company's growth strategy and implement its asset-centric business model. •

Send your personnel announcements to feedback@pharmavoice.com.